| Aug 28 |
Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data
|
| Aug 28 |
Neurocrine Biosciences to Participate at Investor Conferences in September
|
| Aug 28 |
Neurocrine Biosciences: Disappointing Data From A Key Readout Hits The Stock Hard
|
| Aug 28 |
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
|
| Aug 28 |
Neurocrine Stock Hammered After Schizophrenia Drug Lags Two Key Rivals
|
| Aug 28 |
Neurocrine’s mixed schizophrenia data disappoint Wall Street
|
| Aug 28 |
Neurocrine stock dips even as schizophrenia drug meets main goal in study
|
| Aug 28 |
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
|
| Aug 23 |
High Growth Tech And 2 Other Promising Tech Stocks
|
| Aug 16 |
Insider Sale: Director William Rastetter Sells 14,250 Shares of Neurocrine Biosciences Inc (NBIX)
|
